How Regenxbio’s Cash Flows and Valuation Metrics Moved


Apr. 13 2018, Updated 3:47 p.m. ET

Cash flows

Regenxbio (RGNX) spent $57.9 million in operating activities in fiscal 2017 compared to $48.5 million in fiscal 2016. This change was primarily attributable to the increased employee headcount and increases in research and development expenses.

In fiscal 2016, the company generated $19.1 million from investing activities compared to $4.7 million in investing activities in fiscal 2017. Regenxbio generated $84.6 million from financing activities in fiscal 2017 compared with $119,000 in fiscal 2016. This significant change was primarily due to $81.5 million in net proceeds from a follow-on public offering of the company’s common stock and $3 million in proceeds from the exercise of stock options and issuance of common stock under Regenxbio’s employee stock purchase plan. Consequently, the net increase in total cash and equivalents during fiscal 2017 was $21.8 million compared with a net decrease of $29.2 million in fiscal 2016.

Article continues below advertisement

Valuation metrics

Regenxbio’s enterprise value is $700.2 million with an enterprise-value-to-revenue ratio of 67.4x. Its price-to-sales ratio stands at 95.8x and its price-to-book ratio stands at 5.4x. The company’s book value per share is $5.85, while its current ratio, a metric of how effectively the company can meet its short-term obligations, stands at 11.6x.

In the past three months, the share price of Regenxbio has fluctuated from a low of $24 on February 5, 2018, to a high of $38 on March 7, 2018. After that, it again trended in sync with the market drop in recent weeks but witnessed an uptick on April 9, 2018, rising by 20% to close at $31.4.


More From Market Realist

  • BioNano Genomics Saphyr system
    Company & Industry Overviews
    BioNano Genomics (BNGO) Stock Looks Like a Buy, Solid Opportunity
  • Delta aircraft
    Company & Industry Overviews
    Delta Air Lines Updates Mandatory Vaccine Policy, Explained
  • AMC advertisement in walkway
    Company & Industry Overviews
    Why It's Time for Most Investors to Sell AMC Entertainment Stock
  • 100 Thieves founder Matthew Haag
    Company & Industry Overviews
    Why Growing Esports Company 100 Thieves Isn't Publicly Traded
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.